Arvinas (ARVN) Cash from Operations Growth (1y) (2018 - 2026)
Arvinas (ARVN) Cash from Operations Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 158.60% |
| 10 | Arvinas | 530.56 Mn | -84.34 Mn | - | 22.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.16% |
| Dec 31, 2025 | 63.85% |
| Sep 30, 2025 | 53.83% |
| Jun 30, 2025 | -289.66% |
| Mar 31, 2025 | 8.82% |
| Dec 31, 2024 | -1.20% |
| Sep 30, 2024 | -50.94% |
| Jun 30, 2024 | 156.71% |
| Mar 31, 2024 | -6.91% |
| Dec 31, 2023 | -16.71% |
| Sep 30, 2023 | -27.33% |
| Jun 30, 2023 | -12.85% |
| Mar 31, 2023 | -59.72% |
| Dec 31, 2022 | -99.44% |
| Sep 30, 2022 | -109.77% |
| Jun 30, 2022 | -65.82% |
| Mar 31, 2022 | -46.41% |
| Dec 31, 2021 | -23.26% |
| Sep 30, 2021 | 3,144.61% |
| Jun 30, 2021 | -121.47% |